Dengue vaccines: state of the art

Bibliography

• Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. Fields of Virology. In: Knipe DM, Howley PM, editors, 5th edition. Wolters Kluwer and Lippincott Williams & Wilkins, Philadelphia; 2007. p. 1101-52
   Google Scholar
• Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med 2009;9:152-73
   PubMed Web of Science ®Google Scholar
• Dengue and dengue haemorrhagic fever. WHO Factsheet No. 117, 2009. Available from: www.who.int/mediacentre/factsheets/fs117/en/. [Last accessed 30 January 2010]
   Google Scholar
• Global burden of dengue. Pediatric Dengue Vaccine Initiative. Available from: www.pdvi.org/about_dengue/GBD.asp. [Last accessed 30 January 2010]
   Google Scholar
• Eckels KH, Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 2003;61:395-418
   PubMedGoogle Scholar
• Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009;9:678-87
   PubMed Web of Science ®Google Scholar
• Zeng L, Falgout B, Markoff L. Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication. J Virol 1998;72:7510-22
   PubMed Web of Science ®Google Scholar
• Men R, Bray M, Clark D, Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenocity in rhesus monkeys. J Virol 1996;70:3930-7
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Greene S, Kalyanarooj S, Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9
   PubMed Web of Science ®Google Scholar
• Burke DS, Nisalak A, Johnson DE, A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988;38:172-80
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri GP, Bravo J, Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990;42:179-84
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421-67
   PubMed Web of Science ®Google Scholar
• Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 2007;85:43-5
   PubMed Web of Science ®Google Scholar
• Balsitis SJ, Williams KL, Lachica R, Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010;6:e1000790
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010;7:128-39
   Google Scholar
• Laoprasopwattana K, Libraty DH, Endy TP, Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 2005;192:510-19
   PubMed Web of Science ®Google Scholar
• Libraty DH, Acosta LP, Tallo V, A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2009;6:e1000171
   PubMed Web of Science ®Google Scholar
• Hombach J, Barrett AD, Cardosa MJ, Review on flavivirus vaccine development: proceedings of a meeting jointly organized by the World Health Organization and the Thai ministry of public health, 26 – 27 April 2004, Bangkok, Thailand. Vaccine 2005;23:2689-95
   PubMedGoogle Scholar
• Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res 2003;61:469-509
   PubMedGoogle Scholar
• Roehrig JT, Hombach J, Barrett ADT. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008;21:123-32
   PubMed Web of Science ®Google Scholar
• Guy B, Almond JW. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008;31:239-52
   Google Scholar
• Clinical Trials database of the US NIH. Available from: http://clinicaltrials.gov/ct2/results?term=dengue. [Last accessed 4 March 2010]
   Google Scholar
• Putnak JR, Eckels K, Dubois DR. Inactivated dengue virus vaccine. US6254873; 2001
   Google Scholar
• Dittmer DP, Floyd RA. RNA virus vaccines and methods. WO2007094854; 2007
   Google Scholar
• Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010;396:280-8
   PubMed Web of Science ®Google Scholar
• Hasltead SB, Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003;69(Suppl 6):5-11
   Google Scholar
• Bhamarapravati N, Yoksan S. Attenuated strains of dengue virus and their use in a vaccine composition. EP1159968; 2001
   Google Scholar
• Eckels KH, Putnak JR, Dubois DR, Attenuated dengue-1 (-2, -3 & -4) virus vaccine. WO0057908 (WO0057909, WO0057904 & WO0057910); 2000
   Google Scholar
• Kinney R, Kinney CYH, Barban V, Dengue serotype 1attenuated strain. US2006/0292172; 2006
   Google Scholar
• Kinney R, Kinney CYH, Barban V, Dengue serotype 2 attenuated strain. US2007/0026016; 2007
   Google Scholar
• Eckels KH, Putnak JR, Dubois DR, Multivalent dengue virus vaccine. WO00/57907; 2000
   Google Scholar
• Kanesa-thasan N, Sun W, Kim-Ahn G, Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001;19:3179-88
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Lang J, Chanthavanich P, Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002;66:264-72
   PubMed Web of Science ®Google Scholar
• Kitchener S, Nissen M, Nasveld P, Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006;24:1238-41
   PubMed Web of Science ®Google Scholar
• Sun W, Edelman R, Kanesa-Thasan N, Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003;69(Suppl 6):24-31
   Google Scholar
• Edelman R, Wasserman SS, Bodison SA, Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003;69(Suppl 6):48-60
   Google Scholar
• Simasathien S, Thomas SJ, Watanaveeradej V, Safety and immunogenicity of tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008;78:426-33
   PubMed Web of Science ®Google Scholar
• Sun W, Cunningham D, Wasserman SS, Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccines 2009;5:33-40
   PubMed Web of Science ®Google Scholar
• Sanchez V, Giminez S, Tomlinson B, Innate and adaptive immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006;24:4914-26
   PubMed Web of Science ®Google Scholar
• Barban V, Quentin-Millet MJ, Sodoyer R. Live attenuated dengue 3 virus strains. US20080107685; 2008
   Google Scholar
• Monath TP. Yellow fever in vaccines. In: Plotkin SA, Orenstein WA, editors, 3rd edition. WB Saunders Co., Philadelphia; 1997. p. 815-80
   Google Scholar
• Guy B, Guirakhoo F, Barban V, Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;28:632-49
   PubMed Web of Science ®Google Scholar
• Guirakhoo F. Tetravalent dengue vaccines. WO03101397; 2003
   Google Scholar
• Guirakhoo F, Weltzin R, Chambers TJ, Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in non-human primates. J Virol 2000;74:5477-85
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Arroyo J, Pugachev KV, Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001;75:7290-304
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Pugachev K, Arroyo J, Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002;298:146-59
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Pugachev K, Zhang Z, Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004;78:4761-75
   PubMed Web of Science ®Google Scholar
• Guy B, Barbra V, Mantel N, Evaluation of interference between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009;80:302-11
   PubMed Web of Science ®Google Scholar
• Morrison D, Legg TJ, Billings CW, A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in Flavivirus-naive adults. J Infect Dis 2010;201:370-7
   PubMed Web of Science ®Google Scholar
• Quentin-Millet MJ. Dengue chimeric viruses. WO2007093472; 2007
   Google Scholar
• Markoff L, Zeng LL. Dengue viruses that are replication defective in mosquitos for use as vaccines. WO02074963; 2002
   Google Scholar
• Zeng LL, Markoff L. Dengue viruses that are replication defective in mosquitos for use as vaccines. WO0014245; 2000
   Google Scholar
• Whitehead SS, Murphy BR, Hanley KA. Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses. WO02095075; 2002
   Google Scholar
• Men R, Bray M, Clark D, Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenocity in rhesus monkeys. J Virol 1996; 70:3930-7
   PubMed Web of Science ®Google Scholar
• Durbin AP, Karron RA, Sun W, Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30-nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001;65:405-13
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS, McArthur J, rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005;191:710-18
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Murphy BR, Markoff L, Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4. WO03092592; 2003
   Google Scholar
• Whitehead SS, Falgout B, Hanley KA, A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003;77:1653-7
   PubMed Web of Science ®Google Scholar
• Blaney JE, Hanson CT, Hanley KA, Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 2004;4:39
   PubMed Web of Science ®Google Scholar
• Blaney JE, Hanson CT, Firestone CY, Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004;71:811-21
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur J, Marron JA, The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccines 2006;2:167-73
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Blaney JE, Murphy BR. Development of dengue virus vaccine components. WO2008022196; 2008
   Google Scholar
• Butrapet S, Huang CYH, Pierro DJ, Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and non-structural proteins 1 and 3. J Virol 2000;74:3011-19
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N, Butrapet S, Chang J, Infectious dengue 2 virus PDK-53 as quadravalent vaccine. WO9640933; 1996
   Google Scholar
• Durbin AP, McArthur J, Marron JA, rDEN2/4Δ30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. HumVaccines 2006;2:255-60
   Google Scholar
• Blaney JE, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005;79:5516-28
   PubMed Web of Science ®Google Scholar
• Keelapang P, Sittisombut N, Kasinrerk W, Malasit P. Dengue virus mutant strain MBU 01-2002. US2009/0004721; 2009
   Google Scholar
• Brown DT. Insertion of furin protease cleavage sites in membrane proteins and uses thereof. WO2004101598; 2004
   Google Scholar
• Brown DT, Hernandez R. Membrane virus host range mutations and their uses as vaccine substrates. WO0138499; 2001
   Google Scholar
• Suzuki R, Winkelmann ER, Mason PW. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J Virol 2009;83:1870-80
   PubMedGoogle Scholar
• Frolov I, Frolova E, Mason PC. Pseudoinfectious flavivirus and uses thereof. WO2007098267; 2007
   Google Scholar
• Kinney CYH, Beck ET, Kinney RM. Chimeric West Nile/dengue viruses. WO2009134717; 2009
   Google Scholar
• Tangy F, Despres P, Combredet C, Frenkiel MP. New dengue and west Nile viruses proteins and genes coding the foregoing, and their uses in vaccinal, therapeutic and diagnostic applications. WO2004076619; 2004
   Google Scholar
• Tangy F, Lucas-Hourani M, Navarro-Sanchez E, Chimeric polypeptides and their therapeutic use thereof against a flaviviridae infection. WO2006136697; 2006
   Google Scholar
• Brandler S, Lucas-Hourani M, Moris A, Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007;1:e96
   PubMed Web of Science ®Google Scholar
• Despres P, Charneau P, Tangy F, Frenkiel MP. Recombinant lentiviral vector for expression of a flavivirus protein and applications thereof as a vaccine. WO2005111221; 2005
   Google Scholar
• Lai CJ, Men R, Bray M, Jan LR. Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection. WO9203161; 1992
   Google Scholar
• Cardosa MJ, Sutter G, Erfle V. Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines. US20040265324; 2004
   Google Scholar
• Men R, Wyatt L, Tokimatsu I, Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000;18:3113-22
   PubMed Web of Science ®Google Scholar
• Wang D. Genetic vaccine that mimics natural viral infection and induces long lasting immunity to pathogens. WO0191536; 2001
   Google Scholar
• Raviprakash K, Wang D, Ewing D, A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in Rhesus monkeys against all four serotypes of dengue virus. J Virol 2008;82:6927-34
   PubMed Web of Science ®Google Scholar
• Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009;27:6011-21
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antivir Res 2009;84:119-30
   PubMed Web of Science ®Google Scholar
• Donnelly J, Berry K, Ulmer JB. Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 2003;33:457-67
   PubMed Web of Science ®Google Scholar
• Kochel TJ, Porter KR, Raviprakash K, Dengue nucleic acid vaccines that induce neutralizing antibodies. US6455509; 2002
   Google Scholar
• Doris A, Punnonen J, Brinkman AM. Novel flavivirus antigens. WO03102166; 2003
   Google Scholar
• Ramanathan MP, Sardesai NY. Novel vaccines against multiple subtypes of dengue virus. WO2009099716; 2009
   Google Scholar
• Pang X, Dayton AI, Zhang M. Subgenomic replicons of the flavivirus dengue. US20040265338; 2004
   Google Scholar
• Lazo L, Hermida L, Lopez C, Pharmaceutical compound capable of inducing immune protective response against dengue virus having the capsid protein of the dengue virus. US20080311157; 2008
   Google Scholar
• Chan L, Guan M. Dengue virus peptides and methods. US5824506; 1998
   Google Scholar
• Ivy J, Nakano E, Clements D. Subunit immunogenic composition against dengue infection. US6165477; 2000
   Google Scholar
• Sariol C, Mune J, Guzman MG, Process for the expression of genes of the dengue viruses. WO9823754; 1998
   Google Scholar
• Deubel V, Staropoli I. Polyvalent anti-dengue vaccine. WO9718311; 1997
   Google Scholar
• Kelly EP, King AD. Recombinant dengue virus DNA fragment. US6074865; 2000
   Google Scholar
• Clements DE, Coller BAG, Lieberman MM, Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010;28:2705-15
   Google Scholar
• Fan X. The ancestral dengue virus envelope protein sequence. WO2007035530; 2007
   Google Scholar
• Chinea G, Huerta V, Martin M, Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses. WO2007059715; 2007
   Google Scholar
• Guzman MG, Hermida L, Bernardo L, Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010;9:137-47
   PubMed Web of Science ®Google Scholar
• Simmons M, Hayes CG, Porter KR. Recombinant dengue virus envelope protein/maltose-binding protein antigens and subunit vaccine compositions containing said antigens. US5895651; 1999
   Google Scholar
• McDonald W, Powell TJ, Price AE, Becker RS. Compositions of dengue viral proteins and methods of use. WO2009128949; 2009
   Google Scholar
• Bachmann M, Huber A, Ivanova L. Vaccine compositions for the treatment of dengue fever and uses thereof. WO2009130261; 2009
   Google Scholar
• Hermida L, Rodriguez R, Lazo L, Chimeric chains that code for proteins that induce effects directed against viruses. WO2003008571; 2003
   Google Scholar
• Srivastava AK, Putnak JR, Hoke CH, Warren RI. Recombinant vaccine made in E. coli against dengue virus. US6117640; 2000
   Google Scholar
• Chen HW, Leng CH, Chong PCS. Dengue virus peptide vaccine and methods of preparing and using the same. US20090074781; 2009
   Google Scholar
• Batra G, Hapugoda M, Chaudhry S, Tetravalent dengue specific domain III based chimeric recombinant protein. WO2007034507; 2007
   Google Scholar
• Etemad B, Batra G, Raut R, An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 2008;79:353-63
   PubMed Web of Science ®Google Scholar
• Guy B, Forrat R, Lang J, Barban V. Method of immunization against the 4 dengue serotypes. US20080085288; 2008
   Google Scholar
• Barban V, Forrat R, Guy B, Lang J. Method of immunization against the 4 dengue serotypes. US20080014219; 2008
   Google Scholar
• Monath TP, Guirakhoo F, Kanesa-thasan N, Vaccination against dengue virus infection. WO2007021672; 2007
   Google Scholar